Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bostjan Seruga

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|January 6, 2010
Treatment of lung cancerBostjan Seruga, Eitan Amir, Ian Tannock
Nature Reviews. Clinical Oncology|September 23, 2010
Drug resistance in metastatic castration-resistant prostate cancerBostjan Seruga, Alberto Ocana, Ian F Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?Bostjan Seruga, Alberto Ocana, Saroj Niraula, et al.
Expert Opinion on Investigational Drugs|May 21, 2009
Sunitinib in solid tumorsHui K Gan, Bostjan Seruga, Jennifer J Knox
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Do we have to change the way targeted drugs are developed?Alberto Ocana, Eitan Amir, Bostjan Seruga, et al.
Cancer Treatment Reviews|April 14, 2010
Targeting DNA repair in breast cancer: a clinical and translational updateEitan Amir, Bostjan Seruga, Rosario Serrano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?Eitan Amir, Bostjan Seruga, Orit Freedman, et al.
BMJ (Clinical Research Ed.)|December 5, 2009
Amenorrhoea, menopause, and endocrine therapy for breast cancerEitan Amir, Bostjan Seruga, Orit Freedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Failures in Phase III: Causes and ConsequencesBostjan Seruga, Alberto Ocana, Eitan Amir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trialsBostjan Seruga, Lynn Sterling, Lisa Wang, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|January 6, 2010
Treatment of lung cancerBostjan Seruga, Eitan Amir, Ian Tannock
Nature Reviews. Clinical Oncology|September 23, 2010
Drug resistance in metastatic castration-resistant prostate cancerBostjan Seruga, Alberto Ocana, Ian F Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?Bostjan Seruga, Alberto Ocana, Saroj Niraula, et al.
Expert Opinion on Investigational Drugs|May 21, 2009
Sunitinib in solid tumorsHui K Gan, Bostjan Seruga, Jennifer J Knox
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Do we have to change the way targeted drugs are developed?Alberto Ocana, Eitan Amir, Bostjan Seruga, et al.
Cancer Treatment Reviews|April 14, 2010
Targeting DNA repair in breast cancer: a clinical and translational updateEitan Amir, Bostjan Seruga, Rosario Serrano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?Eitan Amir, Bostjan Seruga, Orit Freedman, et al.
BMJ (Clinical Research Ed.)|December 5, 2009
Amenorrhoea, menopause, and endocrine therapy for breast cancerEitan Amir, Bostjan Seruga, Orit Freedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Failures in Phase III: Causes and ConsequencesBostjan Seruga, Alberto Ocana, Eitan Amir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trialsBostjan Seruga, Lynn Sterling, Lisa Wang, et al.
Pageof 9